Literature DB >> 908748

Comparison of aryl hydrocarbon hydroxylase induction in cultured blood lymphocytes and pulmonary macrophages.

T L McLemore, R R Martin, K L Toppell, D L Busbee, E T Cantrell.   

Abstract

Aryl hydrocarbon hydroxylase induction was studied in cultured peripheral blood lymphocytes and pulmonary alveolar macrophages from 15 smokers and 8 nonsmokers with a variety of pulmonary diseases. Enzyme levels in lymphocytes from cigarette smokers cultured in medium without an inducing agent were 57+/-6 mU/10(6) cells (mean+/-SEM), while enzyme levels in lymphocytes from nonsmokers were 20+/-2 mU/10(6) cells (P < 0.001). When lymphocytes were cultured in the presence of the inducing agent, benzo-(a)anthracene, enzyme activity was increased to 168+/-23 mU/10(6) cells in smokers' cells and 99+/-22 mU/10(6) cells in lymphocytes from nonsmokers (P < 0.04). When noninduced enzyme values in cultured macrophages were compared, smokers' cells had enzyme levels of 45+/-5 mU/10(6) cells, whereas nonsmokers had enzyme activity of 24+/-2 mU/10(6) cells (P < 0.002). However, pulmonary macrophages from smokers or nonsmokers, cultured in the presence of benzo(a)-anthracene, had similar levels of induced enzyme activity (P > 0.1). A positive correlation was observed for nonsmokers (r = 0.596, P > 0.1 <0.2) or smokers (r = 0.640, P < 0.04), when enzyme values for noninduced cultures of macrophages and lymphocytes from individual patients were simultaneously compared. Enzyme values for macrophages and lymphocytes cultured in the presence of an inducer also revealed a positive correlation for individual smokers (r = 0.801, P < 0.001) or nonsmokers (r = 0.785, P < 0.01). Inducibility (expressed as fold-induction) for macrophages and lymphocytes from individual patients was also positively correlated (r = 0.889, P < 0.001 for nonsmokers and r = 0.942, P < 0.001 for smokers). These results indicate that the capacity for aryl hydrocarbon hydroxylase induction is similar whether tested in lymphocytes or pulmonary macrophages from this group of pulmonary disease patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908748      PMCID: PMC372453          DOI: 10.1172/JCI108852

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma.

Authors:  G Kellermann; C R Shaw; M Luyten-Kellerman
Journal:  N Engl J Med       Date:  1973-11-01       Impact factor: 91.245

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Aryl hydrocarbon hydroxylase induction by polycyclic hydrocarbons: simple autosomal dominant trait in the mouse.

Authors:  D W Nebert; F M Goujon; J E Gielen
Journal:  Nat New Biol       Date:  1972-03-29

4.  Aryl hydrocarbon hydroxylase activity in pulmonary macrophages and lymphocytes from lung cancer and noncancer patients.

Authors:  T L McLemore; R R Martin; D L Busbee; R C Richie; R R Springer; K L Toppell; E T Cantrell
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

5.  Skin tumor initiating ability of benzo(a)pyrene 4,5- 7,5- and 7,8-diol-9,10-epoxides and 7,8-diol.

Authors:  T J Slaga; A Viaje; D L Betty; W Brachen; S G Buty; J D Scribner
Journal:  Cancer Lett       Date:  1976-11       Impact factor: 8.679

6.  In vitro induction of aryl hydrocarbon hydroxylase in human pulmonary alveolar macrophages by benzanthracene.

Authors:  T L Mclemore; R R Martin
Journal:  Cancer Lett       Date:  1977-05       Impact factor: 8.679

7.  Induction of aryl hydrocarbon hydroxylase in human pulmonary alveolar macrophages and peripheral lymphocytes by cigarette tars.

Authors:  T L McLemore; G A Warr; R R Martin
Journal:  Cancer Lett       Date:  1977-01       Impact factor: 8.679

8.  Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi.

Authors:  C C Harris; H Autrup; R Connor; L A Barrett; E M McDowell; B F Trump
Journal:  Science       Date:  1976-12-03       Impact factor: 47.728

9.  Induction of aryl hydrocarbon hydroxylase in human pulmonary alveolar macrophages by cigarette smoking.

Authors:  E T Cantrell; G A Warr; D L Busbee; R R Martin
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

10.  Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes.

Authors:  S A Atlas; E S Vesell; D W Nebert
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

View more
  6 in total

Review 1.  Genetics of neoplasia--impact of ecogenetics on oncogenesis. A review.

Authors:  D T Purtilo; L Paquin; T Gindhart
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

2.  Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage.

Authors:  G W Hunninghake; J E Gadek; O Kawanami; V J Ferrans; R G Crystal
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

3.  Enhanced benzo(a)pyrene metabolism and formation of DNA adducts in monocytes of patients with lung cancer.

Authors:  H W Rüdiger; V Heisig; E Hain
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

4.  Human alveolar macrophages spontaneous reduction of BSPT salt.

Authors:  F Jaubert; S Barbey; M Grune; C Danel; J Chretien; C Nezelof
Journal:  Histochemistry       Date:  1979-11

5.  Human skin aryl hydrocarbon hydroxylase. Induction by coal tar.

Authors:  D R Bickers; A Kappas
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

6.  Induction of ouabain-resistant mutation and sister chromatid exchanges in Chinese hamster cells with chemical carcinogens mediated by human pulmonary macrophages.

Authors:  I C Hsu; C C Harris; M Yamaguchi; B F Trump; P W Schafer
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.